In a comprehensive genomic study, Huang et al. [62] highlighted the brain metastases-specific increase in ALK fusions, KRAS G12C mutations, and MET amplifications compared to their primary NSCLC counterparts. This evidence concerns the gene ALK and non-small cell lung carcinoma.